Antitrust Antitrust

Leadiant to appeal Italian antitrust sanction that 'undermines' EU policy on orphan drugs

By Nicholas Hirst
  • 02 Jun 2022 17:25
  • 02 Jun 2022 17:25
Leadiant has said it will appeal a 3.5 million-euro Italian antitrust fine ($3.8 million) for raising the price of a life-saving drug to "unjustifiably high" levels.

In a statement, the company said the Tuesday decision risked discouraging companies from bringing drugs to market for rare diseases.

The fine wa

To view the latest version of this document and thousands of others like it, sign-in to MLex or register for a free trial.

Nicholas Hirst

Chief Correspondent


Nicholas covers EU merger review and antitrust investigations for Mlex in Brussels. He previously wrote about EU affairs for Politico Europe, European Voice and PaRR. After earning an LLM in European law from the College of Europe in Bruges, he spent a year working in the competition practice of a leading competition law firm in Brussels 2009-10. He graduated in modern European languages from Oxford University in 2006.

Discover MLex

Stay on top of global regulatory developments

Latest News